Lukas Stanczuk
Overview
Explore the profile of Lukas Stanczuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Dec;
32(2):556-558.
PMID: 38103549
No abstract available.
2.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Mar;
31(7):2089-2104.
PMID: 36945773
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second antigen, CD22, may decrease...
3.
Korhonen E, Murtomaki A, Kumar Jha S, Anisimov A, Pink A, Zhang Y, et al.
J Clin Invest
. 2022 Jun;
132(15).
PMID: 35763346
Vascular endothelial growth factor C (VEGF-C) induces lymphangiogenesis via VEGF receptor 3 (VEGFR3), which is encoded by the most frequently mutated gene in human primary lymphedema. Angiopoietins (Angs) and their...
4.
Munck J, Berdini V, Bevan L, Brothwood J, Castro J, Courtin A, et al.
Mol Cancer Ther
. 2021 Jul;
20(10):1757-1768.
PMID: 34330842
The MAPK signaling pathway is commonly upregulated in human cancers. As the primary downstream effector of the MAPK pathway, ERK is an attractive therapeutic target for the treatment of MAPK-activated...
5.
Urner S, Planas-Paz L, Hilger L, Henning C, Branopolski A, Kelly-Goss M, et al.
EMBO J
. 2018 Dec;
38(2).
PMID: 30518533
Vascular endothelial growth factor receptor-3 (VEGFR3) signalling promotes lymphangiogenesis. While there are many reported mechanisms of VEGFR3 activation, there is little understanding of how VEGFR3 signalling is attenuated to prevent...
6.
Zhang Y, Ulvmar M, Stanczuk L, Martinez-Corral I, Frye M, Alitalo K, et al.
Nat Commun
. 2018 Apr;
9(1):1296.
PMID: 29615616
Incomplete delivery to the target cells is an obstacle for successful gene therapy approaches. Here we show unexpected effects of incomplete targeting, by demonstrating how heterogeneous inhibition of a growth...
7.
Martinez-Corral I, Stanczuk L, Frye M, Ulvmar M, Dieguez-Hurtado R, Olmeda D, et al.
Angiogenesis
. 2016 Jun;
19(3):447.
PMID: 27272322
No abstract available.
8.
Ulvmar M, Martinez-Corral I, Stanczuk L, Makinen T
Genesis
. 2016 Apr;
54(6):350-8.
PMID: 27060598
The Pdgfrb-Cre line has been used as a tool to specifically target pericytes and vascular smooth muscle cells. Recent studies showed additional targeting of cardiac and mesenteric lymphatic endothelial cells...
9.
Martinez-Corral I, Stanczuk L, Frye M, Ulvmar M, Dieguez-Hurtado R, Olmeda D, et al.
Angiogenesis
. 2016 Mar;
19(3):433-45.
PMID: 26993803
The lymphatic system is essential in many physiological and pathological processes. Still, much remains to be known about the molecular mechanisms that control its development and function and how to...
10.
Stanczuk L, Martinez-Corral I, Ulvmar M, Zhang Y, Lavina B, Fruttiger M, et al.
Cell Rep
. 2015 Mar;
10(10):1708-1721.
PMID: 25772358
Pathological lymphatic diseases mostly affect vessels in specific tissues, yet little is known about organ-specific regulation of the lymphatic vasculature. Here, we show that the vascular endothelial growth factor receptor...